Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib or Abemaciclib Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer (Real-world Study)
ChiCTR2200057393Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of palbociclib and abemaciclib in breast cancer (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Progression-Free Survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
palbociclibabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200057393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057393.